Levi Garraway, Roche CMO
Roche wins an edge in the hypercompetitive race for PD-(L)1 market share
Roche is looking to score a class win in the hypercompetitive PD-(L)1 field.
The pharma giant put out word Tuesday morning that their subcutaneous version of Tecentriq looked equivalent to the IV in a pivotal study, putting them on track to jump ahead with an easier-to-administer formulation that could prove distinctly attractive to patients. And now they’re lining up regulatory meetings in a push to achieve a first in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
